A Middle-Aged Beckman Experiences Growing Pains
Executive Summary
In the early 1990s, Beckman was hit by adverse market conditions in its two major businesses, life sciences and clinical diagnostics. A strategic restructuring in the past two years has left it in strong financial shape and focused it on new areas of growth.
You may also be interested in...
Beckman Coulter's Play for High Growth
With the Coulter integration successful, Beckman Coulter looks for high-growth opportunities outside of its traditional businesses. Beckman, through internal efforts in its life sciences business and a series of small alliances, is making a play in genomics and proteomics. In addition to building up near-term revenues, the aim is to find new "content" in the form of assays for its clinical business.
J&J’s Talc Subsidiary Not ‘Financially Distressed’ Enough For Bankruptcy – Third Circuit
The J&J company holding the firm’s liabilities relating to talc litigation, which declared bankruptcy in 2021 shortly after its formation, had its Chapter 11 petition denied by the Third Circuit on 30 January. Attorneys weigh in on the implications for J&J and wider industry.
COVID-19 Vaccine Strain Updates Don’t Exactly Fit Flu Model
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.